{"id":34390,"date":"2021-04-13T07:01:01","date_gmt":"2021-04-13T07:01:01","guid":{"rendered":"https:\/\/tuavaluo.com\/avaluo\/2021\/04\/13\/axesor-eleva-la-calificacion-de-pharmamar-a-bb-y-rebaja-la-perspectiva-a-estable\/"},"modified":"2021-04-13T07:01:01","modified_gmt":"2021-04-13T07:01:01","slug":"axesor-eleva-la-calificacion-de-pharmamar-a-bb-y-rebaja-la-perspectiva-a-estable","status":"publish","type":"post","link":"https:\/\/tuavaluo.com\/avaluo\/2021\/04\/13\/axesor-eleva-la-calificacion-de-pharmamar-a-bb-y-rebaja-la-perspectiva-a-estable\/","title":{"rendered":"Axesor eleva la calificaci\u00f3n de PharmaMar a &#039;BB+&#039; y rebaja la perspectiva a estable"},"content":{"rendered":"<p>La compa\u00f1\u00eda est\u00e1 a la espera de que, en los pr\u00f3ximos d\u00edas, se conozca la decisi\u00f3n de los reguladores sobre el paso a la fase III de su ensayo Aplicov para el uso de su compuesto Aplidin contra el Covid-19. La incertidumbre que genera el hecho de que no se haya conocido a\u00fan esta decisi\u00f3n <strong>ha penalizado a PharmaMar \u00faltimamente en bolsa.<\/strong><\/p>\n<p>Este lunes, <a href=\"https:\/\/www.bolsamania.com\/noticias\/analisis-tecnico\/pharmamar-rellena-parcialmente-gap-alcista-finales-enero-ahora-nunca--7863993.html\" rel=\"noopener noreferrer\" target=\"_blank\" rel=\"nofollow\" ><strong>PharmaMar<\/strong><\/a> se dejaba un 2,33%, hasta los 92,020 euros.<\/p>\n<p>La biotecnol\u00f3gica se mantiene optimista y considera que lograr\u00e1 el &#8216;ok&#8217; de la Agencia Espa\u00f1ola del Medicamento para avanzar en su ensayo contra el coronavirus. Juan Ros, experto de Intermoney, explicaba la semana pasada a Bolsaman\u00eda que, si finalmente no lo lograse, <strong><a href=\"https:\/\/www.bolsamania.com\/noticias\/empresas\/si-aplicov-no-prospera-intermoney-aconseja-relativizar-comprar-pharmamar--7865493.html\" rel=\"noopener noreferrer\" target=\"_blank\" rel=\"nofollow\" >los inversores deber\u00edan intentar mantener la calma porque no es algo tan grave, a nivel resultados, para la compa\u00f1\u00eda.<\/a><\/strong><\/p>\n<p>&#013;<br \/>\nSource: Bolsamania.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La compa\u00f1\u00eda est\u00e1 a la espera de que, en los pr\u00f3ximos d\u00edas, se conozca la decisi\u00f3n de los reguladores sobre&#8230;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[104],"tags":[99],"_links":{"self":[{"href":"https:\/\/tuavaluo.com\/avaluo\/wp-json\/wp\/v2\/posts\/34390"}],"collection":[{"href":"https:\/\/tuavaluo.com\/avaluo\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tuavaluo.com\/avaluo\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tuavaluo.com\/avaluo\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/tuavaluo.com\/avaluo\/wp-json\/wp\/v2\/comments?post=34390"}],"version-history":[{"count":0,"href":"https:\/\/tuavaluo.com\/avaluo\/wp-json\/wp\/v2\/posts\/34390\/revisions"}],"wp:attachment":[{"href":"https:\/\/tuavaluo.com\/avaluo\/wp-json\/wp\/v2\/media?parent=34390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tuavaluo.com\/avaluo\/wp-json\/wp\/v2\/categories?post=34390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tuavaluo.com\/avaluo\/wp-json\/wp\/v2\/tags?post=34390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}